Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23296642 | 1.00 | ADAMTS4 (0.35) | ADAMTS4TP53SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL28981906 | 0.98 | ADAMTS4 (0.34) | ADAMTS4TP53SLC7A5SLC1A3SLC1A2 | |
| SCHEMBL25903467 | 0.81 | — | — | |
| SCHEMBL18125943 | 0.80 | ADAMTS4 (0.37) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL20488172 | 0.80 | ADAMTS4 (0.37) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL29542685 | 0.79 | — | — | |
| SCHEMBL7189450 | 0.78 | ADAMTS4 (0.36) | ADAMTS4TP53SLC7A5GABRR1 | |
| SCHEMBL7189454 | 0.78 | ADAMTS4 (0.36) | ADAMTS4TP53SLC7A5GABRR1 | |
| Lithium Ion SCHEMBL23296547 | 0.77 | PDK1 (0.30) | — | |
| Lithium Ion SCHEMBL23296546 | 0.77 | PDK1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720072-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | disclosed |
| US-20250388598-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| US-20250368661-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| WO-2024249299-A2 | RAS INHIBITORS | Revolution Medicines, Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116209438-A | Treatment of malignant diseases with SHP2 mutations using SOS1 inhibitors | 锐新医药公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-115916194-A | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors | 锐新医药公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115873067-A | RAS inhibitors | 锐新医药公司 | 2023-03-31 | — | — | CN | disclosed |
| US-11608346-B2 | Ras inhibitors | Revolution Medicines, Inc. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-114867735-A | RAS inhibitors | 锐新医药公司 | 2022-08-05 | — | — | CN | disclosed |
| US-20210130369-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368661-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ADAMTS4 3433/4885TP53 9/4885SLC7A5 3636/4885 |
| US-20260078133-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ADAMTS4 4675/4885TP53 24/4885SLC7A5 1913/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | ADAMTS4 3915/4885TP53 119/4885SLC7A5 4017/4885 |
| US-11608346-B2 | Ras inhibitors | KRAS, NRAS, HRAS | ADAMTS4 3433/4885TP53 9/4885SLC7A5 3636/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | ADAMTS4 3316/4885TP53 14/4885SLC7A5 3926/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ADAMTS4 3433/4885TP53 9/4885SLC7A5 3636/4885 |
| US-20250388598-A1 | RAS INHIBITORS | KRAS, NRAS, G3BP2 | ADAMTS4 3870/4885TP53 144/4885SLC7A5 1887/4885 |
| US-20210130369-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | ADAMTS4 3433/4885TP53 9/4885SLC7A5 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.